Proprietario: Istituti Fisioterapici Ospedalieri

“Anti-Biofilm Test” to evaluate the susceptibility of pathogenic bacteria to antibiotics taking into account their ability to form biofilms.

Kit for in vitro diagnosis, on the levels of 6 microRNAs in biological liquids, of mucositis in patients undergoing anti-tumor therapy.

Method capable of classifying TNBC patients at high risk of recurrence and / or metastasis without the need for an invasive biopsy.

Diagnosis of sensitization to contact allergens capable of measuring sensitization and predicting clinical evolution.

Expression pattern of hMENA isoforms as prognostic / theranostic biomarker, as therapeutic targets of solid tumors.

Method of in vitro diagnosis and monitoring of head and / or neck cancer in tissue samples and / or biological fluids.

MicroRNAs capable of predicting response to MAPKi therapy before the initiation of anticancer treatments in metastatic melanoma.

Using microRNAs to target and inhibit TRF2 over-expression in tumors as an alternative to chemotherapy treatment.

Identification of 3 miRNAs to discriminate glioma patients with IDH1 mutations from patients with wild-type (unmutated) genotype

Use of miRNA for the in vitro diagnosis of resistance of tumors to drugs that inhibit the BRAF / MEK pathway (also called MAPK pathway).

Predictive molecular markers of immunotherapy response to assess whether a patient is responsive or resistant to clinical treatments.

The invention offers a vaccine that induces a strong antibody response against HPV type 16 antigens and for the SARS-CoV protein N.

Method for the in vitro diagnosis of the degree of risk of recurrence or persistence of head and neck cancer and related kit.